Letsrab-D Capsule SR is a combination pharmaceutical formulation containing Domperidone 30mg and Rabeprazole 20mg, designed for the effective management of gastroesophageal reflux disease (GERD), dyspepsia, and related upper gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, facilitates gastric motility and accelerates gastric emptying, thereby reducing symptoms such as nausea, vomiting, and bloating. Rabeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, promoting mucosal healing and symptom relief. The sustained-release (SR) formulation ensures a prolonged therapeutic effect, enhancing patient compliance by reducing dosing frequency. Letsrab-D Capsule SR is indicated for patients with acid-related disorders requiring both acid suppression and prokinetic action. It is generally well-tolerated; however, caution is advised in patients with hepatic impairment or those taking medications that may interact with domperidone or rabeprazole. Common adverse effects may include headache, dry mouth, and gastrointestinal disturbances. This combination therapy should be used under medical supervision, with appropriate evaluation of contraindications and monitoring for potential side effects to optimize clinical outcomes.